About:
Enable Biosciences is developing innovative diagnostic tools for early disease detection in Type 1 diabetes and celiac disease. Their proprietary technology platform, ADAP (Antibody Detection and Prediction), utilizes advanced immunoassay techniques to measure autoantibodies with unprecedented sensitivity and specificity. ADAP can detect autoantibodies associated with T1D risk years before symptoms appear, enabling early intervention and potentially preventing or delaying the onset of the disease. Enable Biosciences' innovative approach has the potential to revolutionize the field of early autoimmune disease detection. Enable Biosciences has been awarded a patent for their method of detecting polyclonal antibodies, further enhancing the sensitivity and specificity of their ADAP platform.